Josep Llovet

Josep Llovet, MD

  • PROFESSOR | Medicine, Liver Diseases

Josep M. Llovet is Director of the Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School of Medicine, New York University (USA), and Professor of Research-ICREA in the BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic, University of Barcelona. Professor Llovet obtained his degree in Medicine and Surgery from the University of Barcelona in 1986 and his PhD from the Autonomous University of Barcelona in 1995.


Professor Llovet has been President of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC). He has published more than 225 articles in peer-reviewed journals such as New England Journal of Medicine, Nature , Nature Genetics, Lancet, Cancer Cell, Journal Clinical Investigation, Journal of Clinical Oncology, Lancet Oncology, Gastroenterology and Hepatology (total citations 33.629, total impact factor 2234; h index 77), more than 40 chapters of books, and has delivered more than 450 lectures. Of note, he has been recognized as a) Top-1% cited researcher in Thomson Reuters, 2014, b) Recognized by Nat Medicine 2011 as first author of the most cited paper in all disciplines of cancer for the period 2008-09 (Llovet, NEJM 2008). During the last 5 years he acted as Senior Editor of Clinical Cancer Research, Special Editor of Gastroenterology and Journal of Hepatology and as Director of the Master in Translational Medicine at the University of Barcelona. He has been awarded with the International Hans Popper award (2012), August Pi i Sunyer Award (2010) and Josep Trueta award (2013). He is member of leadership committees in Mount Sinai (Executive Management Committee, Tisch  Cancer Institute) and IDIBAPS (Executive Committee and Director’s Consulting Committee) and Educational Councilor, International Liver Cancer Association (ILCA).

His grant support for the period of 2010-14 includes a total of 23 grants (research 18; educational 5), among which he has been PI of 20, including international projects with competitive funding from the European Commission (FP7- HEALTH, HEPTROMIC, 2010-14; 3M € ), the US National Institute of Health (R01, 2008-13;1.25M $), the Spanish National Health Institute, I+D Program (SA; F-2010-16055; SAF-2013-41027:total: 445K € ) and from the Asociación Española Contra el Cancer (AECC, 2011-2016; 1.2M €). He is currently leading the HCC Genomic Consortium, which includes 6 academic institutions in the US and Europe. This Consortium has organized a tumor tissue bank of 600 fresh frozen tissues and >2000 samples of paraffin-embedded tissue from human hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and rare liver tumors as fibrolamellar carcinoma (FLC) and hepatoblastoma along with clinically annotated data. Regarding his lab team, during these 5 years he has been mentoring 9 Post-Docs and 8 PhD students (2 presented their thesis).


MD, University of Barcelona

Hospital Germans Trias i Pujol